" /> Sugemalimab - CISMeF





Preferred Label : Sugemalimab;

NCIt synonyms : CS 1001; Anti-PD-L1 Monoclonal Antibody WBP 3155; Anti-PD-L1 Monoclonal Antibody CS1001;

NCIt definition : A fully human monoclonal antibody directed against the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sugemalimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells. Anti-PD-L1 monoclonal antibody CS1001 mirrors natural immunoglobulin G4 (IgG4), potentially reducing immunogenicity and other toxicities.;

UNII : 90IQR2I6TR;

CAS number : 2256084-03-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2256084-03-2 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Cejemly;

Molecule name : CS-1001; WBP-315; WBP 315;

NCI Metathesaurus CUI : CL555350;

Codes from synonyms : 36080;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.